Deakin University
Browse

File(s) under permanent embargo

Primary systemic therapy in HER2-amplified breast cancer : a clinical review

journal contribution
posted on 2012-01-01, 00:00 authored by Mustafa Khasraw, R Bell
Primary systemic therapy (PST) in early breast cancer is utilized in locally advanced breast tumors and when breast-conserving surgery is desirable. In addition, the PST setting provides an opportunity to monitor response including histopathological and biomarker examination of the tumor and host tissues before and after systemic therapy. Trastuzumab is a monoclonal antibody targeting the hEGF receptor that is overexpressed in 15–20% of breast tumors. Trastuzumab is effective in prolonging survival when used to treat women with hEGF receptor overexpressed tumors, both in adjuvant and metastatic disease settings. Trastuzumab has also shown promising activity in PST/neoadjuvant studies by achieving high rates of complete pathologic response. This is a review of clinical studies that incorporated trastuzumab in PST and/or neoadjuvant chemotherapy, including the results of recently reported studies using trastuzumab in combination with other novel therapies such as lapatinib or pertuzumab.

History

Journal

Expert review of anticancer therapy

Volume

12

Issue

8

Pagination

1005 - 1013

Publisher

Expert Reviews

Location

London, England

ISSN

1473-7140

eISSN

1744-8328

Language

eng

Publication classification

C1 Refereed article in a scholarly journal

Copyright notice

2012, Expert Reviews